Tabrecta(Capmatinib) Side Effects

A profile of common and serious adverse reactions requiring monitoring.

Side Effects

The most frequently reported adverse reactions associated with TABRECTA include peripheral edema, nausea, musculoskeletal pain, fatigue, vomiting, dyspnea, cough, and decreased appetite. These were observed in 20% or more of patients in clinical trials. The drug also carries warnings for more serious, though less common, adverse reactions such as interstitial lung disease/pneumonitis, hepatotoxicity evidenced by increased liver enzymes, and pancreatic toxicity indicated by elevated amylase and lipase. Laboratory abnormalities commonly include decreased albumin and increased creatinine.

Capmatinib(Tabrecta)
Treatment of metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations.
RELATED ARTICLES
What Are the Side Effects of Capmatinib (Tabrecta)?

Capmatinib (Tabrecta) is a targeted MET kinase inhibitor indicated for the treatment of adult patients with...

Monday, October 13th, 2025, 14:30
/ 1
1 in total
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved